Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ETON vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ETON Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

ETON Overall Winner 6-Pillar Tally: ETON 5 – 1 TLPH Matrix Metrics: ETON 6 – 4 TLPH

As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -1474700.0% operating margin) and revenue trajectory (+157.9% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although ETON compares more favorably head-to-head, both ETON (36.5/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ETON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ETON vs TLPH
ETON NASDAQ Head-to-Head Winner
Eton Pharmaceutcials, Inc. Common Stock
Pharmaceutical Preparations
$64.30
+0.58% 1D
Market Cap $1.8B
TTM Revenue $141M
Forward P/E 19.3x
Beta / 30D Vol 0.63β · 99% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 50.0 Fund 36.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 62.3 · SMA20: $55.23 · SMA50: $55.38
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (ETON 5 – 1 TLPH)

Columns: Metric · ETON · TLPH
1. Valuation Multiples TLPH
Forward P/E 19.3x 1.0x
Trailing P/E 39.9x 1.0x
PEG Ratio N/M N/M
EV / Revenue 12.3x N/M
2. Growth & Scale ETON
Revenue Growth (YoY) +157.9% +0.0%
Earnings Growth (YoY) -12.6% +0.0%
TTM Revenue (USD) $141M $1,000
Market Cap $1.8B $53.7M
3. Profitability & Quality ETON
Gross Margin 71.2% N/A
Operating Margin 31.3% -1474700.0%
Net Profit Margin 35.4% 0.0%
Return on Equity (ROE) 90.6% -143.4%
4. Balance Sheet & Cash Flow ETON
Cash Generation (TTM) $20M -$15M EBITDA
Cash Flow Margin 14.2% N/A
Net Cash / Leverage $32M Net Cash $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ETON
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 59.3% (14th %ile) 118.4% (100th %ile)
Put/Call OI Skew 0.13x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ETON
OpEx & R&D Intensity 39.9% of Rev ($56M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ETON (6) vs TLPH (4)
Institutional Metric ETON TLPH Criterion Row Edge
Market Capitalization
Scale
$1.8B $53.7M Larger Scale ETON
Trailing P/E Ratio
Valuation
39.9x 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
19.3x 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+157.9% +0.0% Higher Growth ETON
Operating Margin (TTM)
Profitability
31.3% -1474700.0% Higher Margin ETON
Net Profit Margin
Profitability
35.4% 0.0% Higher Margin ETON
Return on Equity (ROE)
Capital Efficiency
90.6% -143.4% Higher ROE ETON
52-Week Range Position
Momentum
89% ($14–$71) 20% ($1–$2) Stronger Trend ETON
Beta / 30D Volatility
Risk Regime
0.63β · 99% Vol 1.11β · 58% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
36.5 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite TLPH
Trailing 12M Revenue (USD)
Operating Scale
$141M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 12.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($32M Net Cash) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ETON +48.1 pp
ETON: +27.81% · TLPH: -20.29%
3M Horizon ETON +30.22 pp
ETON: +1.37% · TLPH: -28.85%
6M Horizon ETON +89.93 pp
ETON: +97.91% · TLPH: +7.98%
1Y Horizon ETON +298.93 pp
ETON: +280.92% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ETON vs TLPH. Trailing 12-month operating profitability (ETON 31.3% vs TLPH -1474700.0%) and valuation multiples (ETON 19.3x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ETON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$141M
Gross Margin71.2%
Op. Margin31.3%
ROE / Fwd P/E90.6% · 19.3x
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ETON CONSOLIDATION
59d in phase · OBV ACCUMULATION
Current IV 59.3%
IV Percentile 14th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ETON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ETON Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.8B market capitalization and 31.3% operating margin.
OpEx & R&D Reinvestment 39.9% of Rev ($56M)
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ETON vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -1474700.0% operating margin) and revenue trajectory (+157.9% vs. +0.0% YoY). Defensive Composite Rating Caution: Although ETON compares more favorably head-to-head, both ETON (36.5/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ETON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ETON leads the Growth & Scale pillar: ETON posts +157.9% YoY revenue growth and -12.6% YoY earnings growth on $141M TTM revenue (71.2% gross margin, 31.3% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, ETON generates $141M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, ETON deploys 39.9% of Rev ($56M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. ETON trades at 19.3x Forward P/E, 39.9x Trailing P/E, N/M PEG, and 12.3x EV/Revenue (14.2% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ETON (90.6% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ETON carries 59.3% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.63β · 99% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.